| BIOMARIN PHARMACEUTICAL INC. |
| USA |
| Gesundheit |
| US09061G1013 / 924801 |
| BM8 (Frankfurt) / BMRN (NASDAQ) |
| FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN |
| - |
| https://www.biomarin.com/ |
|
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement t..
>Volltext.. |
| 10148.38 Mio. EUR |
| 13080.28 Mio. EUR |
| 3097.37 Mio. EUR |
| 710.11 Mio. EUR |
| 65.38 Mio. EUR |
| 0.34 EUR |
| 3779.17 Mio. EUR |
| 783.13 Mio. EUR |
| 767.97 Mio. EUR |
| 0.53 |
| 17.26% |
| -88.55% |
| - |
| - |
| - |
| - |
| BIOMARIN |
| 03.11.26 |